Extensively drug-resistant tuberculosis

  title={Extensively drug-resistant tuberculosis},
  author={Philip A Lobue},
  journal={Current Opinion in Infectious Diseases},
  • P. Lobue
  • Published 1 April 2009
  • Medicine, Biology
  • Current Opinion in Infectious Diseases
Purpose of review To describe the origin, epidemiology, diagnosis, treatment, prevention, and control of extensively drug-resistant tuberculosis (XDR TB). Recent findings XDR TB is defined as the occurrence of TB in persons whose Mycobacterium tuberculosis isolates are resistant to isoniazid and rifampin and to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). As of June 2008, XDR TB has been found in 49 countries including… 

Role of fluoroquinolones in the treatment of tuberculosis

The aim of this review is to summarize the current status of fluoroquinolones in shortening the duration of drug-susceptible pulmonary TB and in improving the outcome of MDR-TB/XDR- TB.

Lesson from surveillance of drug-resistant tuberculosis in Gujarat.

  • P. Mohapatra
  • Medicine, Biology
    The Indian journal of medical research
  • 2010
Increase of drug resistance correlates well with the very widespread use of this class of antimicrobials in lower-respiratory, gastrointestinal, genitourinary etc.

Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal.

The association of specific mutations highlighted the strains' high clonality and indicates recent XDR-TB transmission, and the identification of the most frequent resistance-associated mutations will be invaluable in applying X DR-TB molecular detection tests in the region in the near future.

Mycobacterium tuberculosis: drug resistance and future perspectives.

The mode of action and the resistance mechanisms of the principal first- and second-line antitubercular agents, namely isoniazid, ethionamide, ethambutol, D-cycloserine, rifamycins, fluoroquinolones, streptomycin, linezolid and pyrazinamide are described.

[Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease].

  • O. Baylan
  • Medicine, Biology
    Mikrobiyoloji bulteni
  • 2011
A new form of tuberculosis, resistant to all first-and second-line anti-tuberculosis drugs seen in just a few number of cases, has been defined as extremely drug resistant tuberculosis and this is the end point in resistance problem in tuberculosis.

A case of isoniazid-resistant miliary tuberculosis in which tuberculous meningitis paradoxically developed despite systemic improvement

The tuberculous meningitis had worsened paradoxically despite his systemic improvement, although it was successfully treated by the addition of levofloxacin (LVFX) and SM.



Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

  • Hye-Ryoun KimSeung-sik Hwang J. Yim
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
The presence of extensive drug resistance, the presence of comorbidity, and hypoalbuminemia were independent poor prognostic factors in non-HIV-infected patients with MDR-TB.

Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

New anti-TB drug regimens, better diagnostic tests, and international standards for SLD-susceptibility testing are needed for effective detection and treatment of drug-resistant TB.

Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases

In the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis, resistance to the injectable drug capreomycin was an independent predictor for therapy failure in this cohort.

Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research.

  • A. Fauci
  • Medicine, Biology
    The Journal of infectious diseases
  • 2008
Although estimates suggest that the rates of new cases and deaths due to TB show signs of slowing throughout the world recent increases in rates of drug-resistant TB have the potential to reverse these gains.

Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.

  • P. LobueK. Moser
  • Medicine
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2005
INH and RMP resistance remained stable between 1993 and 2002, and future reductions in drug resistance will depend not only on local and national efforts, but also on the success of global interventions.

Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

Surgical resection and fluoroquinolone therapy were associated with improved microbiological and clinical outcomes in the 205 patients studied after adjusting for other variables, and the improvement was statistically significant for surgery and among older patients for fluoroquolone Therapy.

Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.

The threat of MDR TB is decreasing, and the transmission of M. tuberculosis in health-care settings continues to decrease because of implementation of infection-control measures and reductions in community rates of TB.

The emergence of drug-resistant tuberculosis in New York City.

There has been a marked increase in drug-resistant tuberculosis in New York City and previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance.

Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa.

This molecular assay is a highly accurate screening tool for MDR TB, which achieves a substantial reduction in diagnostic delay, with overall performance characteristics that are superior to conventional culture and drug susceptibility testing and the possibility for high throughput with substantial cost savings.